Background: Metformin has been used in Diabetes over prolonged period. We planned this study to evaluate the efficacy of metformin in ADPKD patients at high risk of disease progression.
Materials and methods: This is a single center randomized controlled study with a 2:1 recruitment in intervention and control arm respectively. Patient diagnosed as ADPKD were further stratified according to presence or absence of family history of end stage renal disease before the age of 60 years. Patients with eGFR≤ 45, body mass index ≥30, diabetes were excluded. Metformin was given at 1000mg/day. CT scan was done to assess kidney volumes at baseline and at 1 year. Renal function tests and proteinuria were monitored 3 monthly.
Results: The baseline characteristics were similar in the two groups. The total kidney volumes were 1000.0 ±570.4 ml and 1041.1 ±439.6 ml; and eGFR (estimated glomerular filtration rate) was 82.3±13.2 and 85.1±20.5 ml/min/1.73 m2 in control and intervention groups respectively. The % change in total kidney volume at one year was significantly lesser in the intervention group compared to control group (p=0.005).
Conclusion: Metformin is a promising alternative in ADPKD to slow the progression of kidney volume which is surrogate maker of progression of kidney disease in ADPKD.
Impact Factor
2022: 6.012
This work is licensed under a